The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • e-health SaaS provider Jayex Healthcare (JHL) has appointed Nick Harper as a Non-Executive Director, effective immediately
  • Mr Harper has worked in software development for over 30 years, in local government, investment banking and the aviation sector
  • The company has also completed a $700,000 placement, funds from which will support the rollout of new products for the Jayex Connect Platform and enable the company to explore new acquisition opportunities
  • In early afternoon trade, shares were up 36.7 per cent at 4.1 cents

e-health SaaS provider Jayex Healthcare (JHL) has appointed Nick Harper as a Non-Executive Director, effective immediately.

Mr Harper is based in the United Kingdom and has worked in software development for over 30 years, in local government, investment banking and the aviation sector.

He has worked on implementing and maintaining various types of software systems including batch valuation systems and real-time data processing and more recently been focused on product management and ownership.

Jayex Executive Chairman Michael Boyd said he was delighted that Mr Harper had agreed to join the board.

“His experience, energy and knowledge will enhance the leadership of the company. I look forward to working with him going forward.”

Completes $700,000 placement

The company has also placed 25,000,000 shares to institutional and sophisticated investors at 2.8 cents, raising $700,000.

The funds from the placement will support the rollout of new products on the Jayex Connect Platform, used by GPs and hospital in Australia, New Zealand and the United Kingdom.

New offering to be brought to the platform includes a remote monitoring application for fever and flu-like symptoms, licenced from Lifespot Health.

The Executive Chairman said that after 40 years of operations, the company is transitioning to a cloud-based model.

“Our transition to a cloud-based model is allowing us to evolve the platform, deploy new products rapidly, and ultimately create the opportunity to grow revenue by deepening our relationship with our long-standing existing customer base, and continue to expand into new sites.”

Additionally, funds from the equity raise will enable the company to explore new acquisition opportunities as they arise.

Shares were up 36.7 per cent at 4.1 cents at 1:30 pm AEST.

JHL by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system